Safety of the DPP-4 Inhibitor, α-glucosidase Inhibitors, Glitazones and SGLT-2 Inhibitors as Add-on Therapy with Metformin in Medication of Type 2 Diabetes Mellitus
International Journal of Diabetes and Endocrinology
Volume 1, Issue 1, December 2016, Pages: 13-15
Received: Nov. 2, 2016; Accepted: Dec. 29, 2016; Published: Jan. 23, 2017
Views 2221      Downloads 68
Authors
Alok Raghav, Rajiv Gandhi Centre for Diabetes & Endocrinology, J. N. Medical College, Aligarh Muslim University, Aligarh, India
Jamal Ahmad, Diabetes and Endocrinology Super Speciality Centre HIG-1 Avantika, Aligarh U.P., India
Maaz Ozair, Rajiv Gandhi Centre for Diabetes & Endocrinology J. N. Medical College, Aligarh Muslim University, Aligarh, India
Saba Noor, Rajiv Gandhi Centre for Diabetes & Endocrinology J. N. Medical College, Aligarh Muslim University, Aligarh, India
Zeeshan Ahmad Khan, Molecular Rythm Laboratory, Institute of Bio-Resources and Sustainable Development, Takyel, Imphal, Manipur, India
Brijesh Kumar Mishra, Department of Endocrinology, Guru Teg Bahardur Hospital, University of Delhi, New Delhi, India
Article Tools
Follow on us
Abstract
Optimal successful management of type 2 diabetes mellitus (T2DM) remains an elusive goal ever. Add on therapies with metformin addressing the prime impaired insulin secretion shows promise in achieving strict and effective glycemic control. The aim of this study was to assess the efficacy of DPP-4 inhibitors, α-glucosidase inhibitors, glitazones and SGLT-2 inhibitors as add-on options with metformin to treat patients with T2DM. The primary outcome of this study was a reduction in diabetes and its associated complication along with strict glycemic control with add-on agents used with metformin.
Keywords
Diabetes Mellitus, SGLT-2 Inhibitors, Glitazones, α-glucosidase Inhibitors, Metformin
To cite this article
Alok Raghav, Jamal Ahmad, Maaz Ozair, Saba Noor, Zeeshan Ahmad Khan, Brijesh Kumar Mishra, Safety of the DPP-4 Inhibitor, α-glucosidase Inhibitors, Glitazones and SGLT-2 Inhibitors as Add-on Therapy with Metformin in Medication of Type 2 Diabetes Mellitus, International Journal of Diabetes and Endocrinology. Vol. 1, No. 1, 2016, pp. 13-15. doi: 10.11648/j.ijde.20160101.13
Copyright
Copyright © 2016 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
References
[1]
Saydah SH, Fradkin J, Cowie CC. 2004. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 291:335–342.
[2]
Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B. 2008. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: update regarding thiazolidinediones: a consensus statement from the American Diabetes Association and the European. Association for the Study of Diabetes. Diabetes Care 31:173–175.
[3]
Nathan DM, Davidson MB, DeFronzo RA, Heine RJ, Henry RR, Pratley R, Zinman B. 2007. Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care 30:753–759.
[4]
DeFronzo RA, Fleck PR, Wilson CA, Mekki Q. 2008. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study. Diabetes Care 31:2315–2317.
[5]
Vilsboll T, Agerso H, Krarup T, et al. 2003. Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. J ClinEndocrinolMetab, 88:220–4.
[6]
Nathan DM, Davidson MB, DeFronzo RA, et al. 2007. Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care, 30:753–9.
[7]
Campbell LK, White JR, Campbell RK. 1996. Acarbose: its role in the treatment of diabetes mellitus. Ann Pharmacother, 30:1255–62.
[8]
Akanuma Y, Kosaka K, Toyoda T, et al. 1996. Clinical evaluation of a new oral hypoglycemic agent CS-045 in combination with insulin [abstract]. Diabetologia; 39 (suppl 1): A232.
[9]
Fonseca VA, Valiquett TR, Huang SM, et al. 1998. Troglitazonemonotherapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, controlled study. J ClinEndocrinolMetab; 83:3169-3176.
[10]
Horton ES, Whitehouse F, Ghazzi MN, et al. 1998. Troglitazone in combination with sulfonylurea restores glycemic control in patients with type 2 diabetes. Diabetes Care; 21:1462-1469.
[11]
Mikhail N. 2006. Exenatide: a novel approach for treatment of type 2 diabetes. South Med J, 99:1271–9.
[12]
Mikhail N. 2008. Incretinmimetics and dipeptidyl peptidase inhibitors in clinical trials for the treatment of type 2 diabetes. Expert OpinInvestig Drugs, 17:845–53.
[13]
Singh AK. 2014. Deciding oral drugs after metformin in type 2 diabetes: An evidence-based approach. Indian Journal of Endocrinology and Metabolism.; 18(5):617-623. doi:10.4103/2230-8210.139214.
[14]
Benjamin M. Scirica,2016. The Safety of Dipeptidyl Peptidase 4 Inhibitors and the Risk for Heart Failure. JAMA Cardiol.1(2):123-125.
[15]
Van de Laar FA, Lucassen PLBJ, Akkermans RP, et al. 2006. Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose. Cochrane Database Syst, Rev doi: 10.1002/14651858.CD005061.pub2.
[16]
http://www.nytimes.com/health/guides/disease/type-2-diabetes/medications.html.
ADDRESS
Science Publishing Group
1 Rockefeller Plaza,
10th and 11th Floors,
New York, NY 10020
U.S.A.
Tel: (001)347-983-5186